Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...

HCB101, a novel Fc-based anti-SIRPα-CD47 fusion protein, has received orphan drug designation (ODD) from the FDA for the ...

In an interview with Targeted Oncology, Erin Crane, MD, MPH, discusses PARP inhibitor restrictions in gynecologic oncology.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

Discover how precision lung cancer care tackles gene fusions, new HER2/ROS1/ALK drugs, expanded screening, and liquid ...

Minimal residual disease (MRD) refers to the small number of myeloma cells that may remain after treatment and are not detectable using conventional response criteria. In multiple myeloma, MRD ...

An ongoing phase 2 trial (NCT07222579) has seen early success with a new subcutaneous formulation of blinatumomab (Blincyto) in a patient with CD19-positive mixed phenotype acute leukemia (MPAL), a ...

In this concluding segment, Dr Shaheen focuses on how shared decision making and quality of life considerations guide treatment selection in later line pancreatic neuroendocrine tumor care. She ...

IDH -mutant gliomas represent a rare subset of brain tumors, affecting approximately 12% to 20% of adult patients with glioma. 1 Typically diagnosed in younger populations, these tumors generally ...

Adjuvant selpercatinib boosts event-free survival after surgery in early-stage RET fusion-positive NSCLC, signaling a ...

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and ...

The FDA accepted the new drug application for iberdomide based on minimal residual disease negativity benefit shown in the ...